SAVED
File name .JPG
File alt. text
Image should be px wide x px tall.
Select Image
home - Liver - Hepatopulmonary Disorders - Hepatic hydrothorax Written by Dr Sebastian Zeki

Hepatic hydrothorax

Written by Dr Sebastian Zeki Hepatic hydrothorax Thoracentesis —Therapeutic thoracentesis is the most effective way of reducing large effusions (>1.5 liters). After thoracentesis, diuretics should be started to prevent reaccumu-lation of fluid.Transjugular intrahepatic portosystemic shunt (TIPS) — Response rates in the range of 70 to 80 %.Considerin Child-Pugh score < 10 and < 60yrs with no hepatic encephalopathy. Pleurodesis —Very difficult to treat with chemical pleurodesis as cant keep pleaural surfaces opposed for long enough Thoracoscopic repair —A diaphragmatic repair involving a pleural flap and surgical mesh reinforcement has been described but experience is limited.Liver transplantation — Management -The patient should be assessed for liver transplantation and relieve symptoms.-Treat largely as per ascites.-Chest tubes should not be placed as can result in massive protein and electrolyte depletion, infection, renal failure, and bleeding.-Once a chest drain has been inserted, it is impossible to remove the tube because of the continuous reaccumulation of fluid.Sodium restriction and diuretics is necessary.If a patient develops a refractory hydrothorax the options include repeated thoracentesis, TIPSS, pleurodesis, and surgical repair of defects in the diaphragm. DiagnosisIt is right sided in 85 % of patients.It is left sided in 13 % of patients.It is bilateral in 2 % of patients.Up to 20 % of patients will have evidence of infection or a cause of pleural effusion other than hepatic hydr-thorax.These are transudates (The SAAG >1.1 g/dL as in PHTN).In uncomplicated hepatic hydrothorax, the cell count is low (<500 cells).In cases where the diagnosis is uncertain, an intraperitoneal injection of 99mTc-sulphur colloid or 99mTc-human serum albumin can be helpful.The optimal time to do an isotope study is shortly after therapeutic thoracentesis, when the fluid is reaccum-lating in the pleural cavity. Clinical ManifestationsIt presents as a pleural effusion.13% develop "spontaneous bacterial empyema" (SBEM) (polymorphonuclear cell count >500 cells/mm3 or positive culture with exclusion of a parapneumonic effusion).Mortality of SBEM is as high as 20 %, even with anti-microbial therapy.50% are associated with SBP.The aetiologic agents are the same as SBP. PathogenesisIt is due to ascites passing from the peritoneal to the pleural cavity through small diaphragmatic defects (<1cm) in tendinous part.The negative intrathoracic pressure generated during inspiration favors the passage of fluid from the intra-abdominal to the pleural space.Many patients have only mild or no clinically detectable ascites.

Related Stories

•Risk Factors for Acute Respiratory Distress Syndrome in Patients after Living Donor Liver Transplant

•Hepatopulmonary syndrome in children and adolescents with portal hypertension in Brazil: A multicenter study

•Point-of-Care Agitated Saline Contrast Echocardiography in the Diagnosis of Respiratory Failure: A Case of Hepatopulmonary Syndrome With Decompensated Heart Failure

•Impact of Age on Mortality and Decompensation Events in Patients With Liver Cirrhosis: A Multicenter, Propensity Score Matched Study

•The Canadian Hepatopulmonary Syndrome Program: A Longitudinal Liver Transplant Experience